1. Home
  2. RAND vs IXHL Comparison

RAND vs IXHL Comparison

Compare RAND & IXHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Rand Capital Corporation

RAND

Rand Capital Corporation

HOLD

Current Price

$15.02

Market Cap

41.2M

Sector

Finance

ML Signal

HOLD

Logo Incannex Healthcare Inc.

IXHL

Incannex Healthcare Inc.

HOLD

Current Price

$0.43

Market Cap

49.1M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
RAND
IXHL
Founded
1969
2001
Country
United States
Australia
Employees
N/A
N/A
Industry
Finance: Consumer Services
Sector
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
41.2M
49.1M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
RAND
IXHL
Price
$15.02
$0.43
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
3.2K
23.8M
Earning Date
11-07-2025
11-14-2025
Dividend Yield
11.12%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$7,327,287.00
$12,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$13.25
$0.08
52 Week High
$31.89
$2.25

Technical Indicators

Market Signals
Indicator
RAND
IXHL
Relative Strength Index (RSI) 63.36 59.02
Support Level $13.95 $0.35
Resistance Level $15.49 $0.50
Average True Range (ATR) 0.39 0.03
MACD 0.18 0.02
Stochastic Oscillator 78.79 68.63

Price Performance

Historical Comparison
RAND
IXHL

About RAND Rand Capital Corporation

Rand Capital Corp is a closed-end, externally managed, non-diversified investment company. The company's investment objective is to generate current income and, when possible, complement its current income with capital appreciation by focusing its debt and related equity investments in privately-held, lower middle market companies with committed and experienced managements in a broad variety of industries. It predominantly invests in higher-yielding debt instruments.

About IXHL Incannex Healthcare Inc.

Incannex Healthcare Inc is a clinical stage pharmaceutical company developing medical cannabis products for the treatment of Obstructive Sleep Apnea (OSA), Traumatic Brain Injury (TBI)/Concussion, Rheumatoid Arthritis, Inflammatory Bowel Disease, and Inflammatory Lung Conditions. The company has an Australian license to import, export, and distribute medicinal cannabis products and has launched a line of cannabinoid products. The Company operates and manages its business as one reportable and operating segment, which is the Research and Development of the use of psychedelic medicine and therapies.

Share on Social Networks: